Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981492 | 1.00 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL19890114 | 1.00 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL23768525 | 0.87 | CA1 (0.52) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14587570 | 0.85 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL23387089 | 0.85 | CA1 (0.43) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14538694 | 0.85 | CA1 (0.59) | CA1CA2TSHRCASRMAPK1 | |
| SCHEMBL7955616 | 0.85 | CA1 (0.59) | CA1CA2TSHRCASRMAPK1 | |
| SCHEMBL30950123 | 0.85 | CA1 (0.59) | CA1CA2TSHRCASRMAPK1 | |
| SCHEMBL3428431 | 0.83 | ADRB2 (0.40) | CA1CA2CA7CA9CASR | |
| SCHEMBL3428434 | 0.83 | ADRB2 (0.40) | CA1CA2CA7CA9CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024218290-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218288-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| CN-116322759-A | Phospholipid compounds and uses thereof | 吉利德科学公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | SIRIUS THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | PHAX, CPSF6, RNGTT | CA1 3951/4885CA2 4663/4885CA7 3881/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | CA1 3947/4885CA2 4673/4885CA7 4057/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | CA1 4810/4885CA2 4859/4885CA7 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.